Ad hoc announcement pursuant to Art. 53 LR

Burgdorf, 29.09.2023, 7:00 a.m. – Ypsomed (SIX: YPSN) announces a change in its Executive Board. After more than twenty years, Niklaus Ramseier will hand over his functions as Chief Financial Officer (CFO) on 31 March 2024 and will continue to be available to the company for strategic projects. His successor is Samuel Künzli, who will start his position as CFO on 01 April 2024.

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) has concluded a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors. The autoinjectors will be used to administer drugs for the self-treatment in various metabolic indications. Ypsomed is in the process of substantially increasing its annual manufacturing capacity in several steps until 2031.

Press Releases Ypsomed Group

Burgdorf – The Annual General Meeting of Ypsomed Holding AG (SIX: YPSN) approved all proposals of the Board of Directors on 28 June 2023. More than 360 shareholders attended the event in Burgdorf. They confirmed all members of the Board of Directors in their office and re-elected Gilbert Achermann as Chairman of the Board of Directors.


People with acute and chronic conditions are supported in their self-treatment by the digital therapy management of Ypsomed and S3 Conncted Health.

Burgdorf – Ypsomed (SIX: YPSN) will expand its offering of digital health solutions together with S3 Connected Health in the future. S3 Connected Health, headquartered in Dublin, Ireland is a specialist digital health partner for life science companies. The new offering will allow Ypsomed’s biopharma customers to quickly launch therapy-specific digital patient solutions. People with acute and chronic diseases can thus be supported fully in their therapy management and the outcome of their treatment can be enhanced.

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 497.5 million in the 2022/23 financial year (previous year: CHF 464.8 million). Adjusted for the effect of the divestment of DiaExpert, continuing business demonstrated growth of 16%, or approximately 19% currency adjusted. The reported growth in turnover corresponds to a growth of 7% compared to the previous year. At constant exchange rates compared to the previous year, this would have represented an increase of around 10%. With this growth, the company has significantly increased both its operating profit (EBIT) from CHF 28.6 million to CHF 60.6 million as well as more than doubled its net profits to CHF 51.3 million (previous year CHF 23.1 million). Ypsomed confirms the outlook for the 2023/24 financial year.